GILEAD SCIENCES, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B |
| Operating income | $10.0B | $1.7B | $7.6B | $7.3B | $9.9B |
| Cost of revenue | $6.2B | $6.3B | $6.5B | $5.7B | $6.6B |
| Cash from operations | $10.0B | $10.8B | $8.0B | $9.1B | $11.4B |
| Capital expenditure | $563.0M | $523.0M | $585.0M | $728.0M | $579.0M |
| Free cash flow | $9.5B | $10.3B | $7.4B | $8.3B | $10.8B |
| Share repurchases | $1.9B | $1.1B | $1.0B | $1.4B | $546.0M |
| Impairments | $590.0M | $4.2B | $50.0M | $2.7B | $0 |
| Total assets | $59.0B | $59.0B | $62.1B | $63.2B | $68.0B |
Shares outstanding 1.2B · Free float 74.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.
Recent filings
- May 20, 2026 8-K
- May 7, 2026 10-Q
- May 7, 2026 8-K
- May 4, 2026 8-K
- April 28, 2026 8-K
- February 24, 2026 10-K
- February 23, 2026 8-K
- February 10, 2026 8-K